Comparative Pharmacology
Head-to-head clinical analysis: CUVRIOR versus DEPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUVRIOR versus DEPEN.
CUVRIOR vs DEPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CUVRIOR (trientine) is a copper-chelating agent that forms stable complexes with copper, enhancing its excretion in urine. It also reduces intestinal absorption of copper.
Penicillamine is a chelating agent that forms soluble complexes with heavy metals (e.g., copper, mercury, lead) and promotes their renal excretion. In rheumatoid arthritis, it reduces rheumatoid factor and immune complexes, and inhibits collagen cross-linking.
300 mg subcutaneously once daily.
250 mg orally 4 times daily, target dose 1000-1500 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life is approximately 0.9–1.5 hours; however, pharmacodynamic effects (copper mobilization) persist for 24–48 hours.
1.5-4 hours; prolonged to 6-12 hours in renal impairment; clinical context: dosing interval adjustments needed in CKD.
Primarily hepatobiliary; unchanged drug and metabolites excreted in feces. Renal elimination accounts for <5% of the administered dose.
Renal: 50% as unchanged drug; biliary/fecal: minor, <5%.
Category C
Category C
Chelating Agent
Chelating Agent